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Abstract. Vitamin A and zinc are important for immune function and may improve host defense against malaria
and reduce the risk of adverse pregnancy outcomes. Our objective was to determine whether daily oral supplemen-
tation with either or both nutrients starting in the first trimester reduces the risk of placental malaria and adverse
pregnancy outcomes. We undertook a randomized, double-blind placebo-controlled trial with a factorial design
among 2,500 human immunodeficiency virus–negative primigravid or secundigravid pregnant women in their first
trimester of pregnancy in Dar es Salaam, Tanzania. We randomly allocated equal numbers of participants to 2,500 IU
of vitamin A, 25 mg of zinc, both 2,500 IU of vitamin A and 25 mg of zinc, or a placebo until delivery. A total of
625 participants were allocated to each treatment group. Our primary outcome, placental malaria infection (past or cur-
rent), was assessed in all randomized participants for whom placental samples were obtained at delivery (N = 1,404),
which represents 56% of total participants and 62% of all pregnancies lasting 28 weeks or longer (N = 2,266). Birth
outcomes were obtained for 2,434 of the 2,500 randomized participants. Secondary outcomes included small for
gestational age (SGA) births and prematurity. All analyses were intent to treat. Those who received zinc had a lower
risk of histopathology-positive placental malaria compared with those who did not receive zinc (risk ratio = 0.64,
95% confidence interval = 0.44, 0.91), but neither nutrient had an effect on polymerase chain reaction–positive
malaria, SGA, or prematurity. No safety concerns were identified. We recommend additional studies in other geo-
graphic locations to confirm these findings.
INTRODUCTION
Malaria causes nearly 200 million clinical cases and
approximately half a million deaths each year, primarily in
sub-Saharan Africa.1 The risk of malaria increases during
pregnancy,2 a period during which its prevention is espe-
cially important. Not only do pregnant women experi-
ence greater severity of illness compared with nonpregnant
women,2 but studies have shown strong associations
between prenatal malaria and maternal anemia,2 fetal loss,
low birthweight, and infant mortality.2 Improving preventive
measures that specifically target malaria in pregnancy is a
global health priority.3
The role of nutritional status in susceptibility to and
severity of malaria has long been recognized.4 Laboratory
and observational studies have suggested a protective
role against malaria for vitamin A and zinc,5–9 two micro-
nutrients central to immune function, though some have
been limited in their ability to distinguish nutritional defi-
ciency from depletion that occurs during the acute-phase
response to infection. Clinical trials conducted among chil-
dren have inconsistently demonstrated a clinical benefit of
both nutrients10–16 in preventing malaria and related out-
comes. Two small clinical trials have been conducted thus
far among pregnant women and have shown no clear evi-
dence of benefit against malaria from either nutrient.17,18
Both zinc and vitamin A have been examined in relation
to pregnancy complications, including preterm birth and
reduced fetal growth. Meta-analyses of existing evidence
suggest zinc supplementation may moderately reduce pre-
term birth though neither zinc nor vitamin A supplemen-
tation improve fetal growth.19,20 However, the quality of
available evidence is variable, and few studies have evalu-
ated the impact of supplementation in early pregnancy.
Using a factorial design, we therefore conducted a ran-
domized, double-blind, placebo-controlled trial of vitamin
A and zinc to determine whether daily oral administration
of either or both of these nutrients starting in the first tri-
mester reduces the risk of placental malaria and adverse
pregnancy outcomes among pregnant women in Dar es
Salaam, Tanzania.
METHODS
Study design and participants. This randomized, double-
blind, placebo-controlled trial was implemented at 8 ante-
natal care clinics in the urban Temeke and Ilala districts
of Dar es Salaam, Tanzania. The trial was registered
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at ClinicalTrials.gov on April 30, 2010, as NCT0111478.
This report has been prepared in accordance with Consoli-
dated Standards of Reporting Trials (CONSORT) guidelines.
Eligible participants were in their first trimester of preg-
nancy, primigravida or secundigravida, human immuno-
deficiency virus (HIV) uninfected, and intending to stay in
Dar es Salaam for at least 6 weeks after delivery. Parti-
cipants were recruited at their first antenatal care visit or
through a demographic surveillance system (DSS) that was
established in the Temeke District to identify early preg-
nancies in the population. The DSS consisted of two types
of operations: 1) a cross-sectional census that enumerated
the age and gender of the residents of all households
within the geographic location and 2) repeated visits every
2 months to the households of all nulli- and primiparous
reproductive-aged women and ascertainment of pregnancy
status through a urine test. All first trimester pregnancies
identified though the DSS were referred for enrollment at
the nearest study clinic. Although initially only women who
were less than 8 weeks’ gestation were considered eligible,
the gestational cutoff for eligibility was raised to 13 weeks
in December 2010 because of low enrollment due to the
challenge of identifying early pregnancies. Gestational age
was estimated using the first date of last menstrual period
(LMP). Between July 12, 2010, and September 17, 2013,
101,184 women were screened for eligibility. Follow-up was
completed in June 2014.
HIV testing was performed at the first clinic visit using two
rapid assays (Alere Determine Walnut Creek, CA, followed by
Uni-Gold HIV 1/2; Trinity Biotech; Wicklow, Ireland). Discrep-
ant results were confirmed using enzyme-linked immunosor-
bent assay (Enzygnost HIV Integral II; Siemens, Marburg,
Germany) at the Muhimbili University of Health and Allied
Sciences (MUHAS) clinical research laboratory. All women
received pre- and posttest counseling. Those who tested
positive were referred for standard prenatal care services
including antiretroviral therapy. Women who tested HIV
negative and provided written informed consent for partici-
pation in the trial were enrolled the same day.
Randomization and masking. Participants were individ-
ually randomized in equal numbers to receive single tablets
containing one of the following regimens: 1) 2,500 IU vita-
min A, 2) 25 mg of zinc (as zinc sulfate), 3) both 2,500 IU
vitamin A and 25 mg zinc, or 4) placebo and instructed to
take the regimen orally each day until delivery. The tablets
were indistinguishable from one another in appearance
and taste. Allocation to treatment groups was performed
according to a computer-generated randomization sequence
using blocks of size 20 by a scientist not involved in the
data collection. Neither the participants nor the study per-
sonnel had access to the masking information. Each study
clinic was issued regimen bottles that were prelabeled
according to this sequence by study pharmacists who had
no contact with participants. At enrollment, each partici-
pant was assigned to the next numbered bottle at their
site. The study remained blinded until all trial assess-
ments and database cleaning were completed, at which
time study staff analyzing the data were given access to
treatment assignments.
Procedures. Enrolled participants completed background
and food frequency questionnaires, underwent a full clinical
examination, provided a blood sample that was tested for a
complete blood count (CBC; Ac·T 5diff AL [Beckman
Coulter, Miami FL]) at the MUHAS clinical research labora-
tory, and were given a 45-day supply of study regimen. In
accordance with Tanzanian standard of care, participants
were also provided with iron (60 mg daily) and folic acid
(5 mg daily) supplements and vouchers for insecticide-
treated bednets issued through a government program.
Participants attended monthly visits at study clinics until
delivery. At each visit, participants were administered a
health questionnaire, given an obstetric examination, and
provided with a 45-day supply of regimen. Study staff col-
lected used pill bottles at each visit and counted remaining
pills. At 20 and 30 weeks’ gestation, all participants were
provided with intermittent preventive treatment in pregnancy
malaria prophylaxis in the form of 1,500 mg sulfadoxine
and 75 mg pyrimethamine per standard of care in Tanzania.
Women were screened by clinic staff for malaria symptoms
and tested for malaria parasites as needed. Incident cases
were managed according to the Tanzanian Ministry of
Health and Social Welfare guidelines.21
Considerable effort was made to reduce loss to follow-up
including limiting enrollment to women who intended to
deliver within the study area, and close follow-up of all
enrolled women, especially in the last weeks of pregnancy.
Nonetheless, some participants later left Dar es Salaam for
cultural reasons (e.g., at the request of their mothers or
in-laws) or delivered at a non-study facility. Birth out-
comes were obtained for 2,434 of the 2,500 randomized
participants. On-call midwives documented birth outcomes,
obtained blood samples for a CBC, and collected, examined,
and sampled placentas following a standardized protocol
after onsite training by a placental pathologist. Participants
also attended a 6-week postpartum clinic visit during which
they were administered questionnaires pertaining to their
health and their infants’ health and both underwent a physi-
cal examination.
Outcomes. Placental malaria was evaluated using both
histopathology and polymerase chain reaction (PCR). Tis-
sue from fresh sampled placentas was divided for both
uses. Histopathologic infections were defined as the pres-
ence of malaria pigment or parasitized erythrocytes on the
slides. Any evidence of placental malaria, whether acute,
chronic, or past, was scored as positive. For histopatho-
logic examination, tissue from a central parenchymal section
of the placenta was formalin fixed, embedded, sectioned,
and stained using hematoxylin and eosin stain. Slides were
examined using light microscopy and under polarized light
for the presence of hemozoin and parasitized erythrocytes. A
single placental histopathologist (Drucilla Roberts), who was
masked to treatment groups and clinical history, classified all
slides. Diagnoses were externally confirmed in a subset of
100 slides. Samples from 1,361 of the 1,404 obtained pla-
centas (97%) underwent histopathologic examination. For
the nucleic acid studies, tissue was stabilized in RNAlater
(Qiagen, Hilden, Germany) and homogenized. Genomic DNA
was extracted using DNeasy (Qiagen). Taqman® qRT-PCR
(Thermo Fisher Scientific, Waltham, MA) was used for amplifi-
cation using published primer and probe sets (Plasmodium
falciparum-specific22 and general Plasmodium 18S rRNA
genes23). The tissue was then tested for PCR inhibitors.
Positive and negative controls were included on each plate
for quality assurance. PCR-detected infections were defined
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as the detection of Plasmodium DNA through PCR amplifi-
cation. Samples from 1,158 of the 1,404 obtained placentas
(82%) underwent nucleic acid studies.
A number of secondary outcomes were also assessed.
These included maternal hemoglobin, infant birthweight,
low birthweight (< 2,500 g), very low birthweight (< 2,000 g),
small for gestational age (SGA; below 10th percentile for
gestational age births, based on the Alexander growth stan-
dard24 and the INTERGROWTH-21st standard),25 placental
weight, maternal hospitalizations during pregnancy, mater-
nal death, fetal loss (miscarriage and stillbirth), preterm birth
(< 37 and < 34 weeks gestational age), perinatal death
(> 28 weeks of gestation to 7 days after birth), child death
(delivery until 6 weeks postpartum), and prevalence of
maternal anemia (hemoglobin [Hb] < 11g/dL) and severe
maternal anemia (Hb < 8.5 g/dL).
Statistical analysis. A sample size of 2,500 was deter-
mined to provide at least 80% power at a 5% significance
level to detect a 35% effect of each intervention on placen-
tal malaria risk assuming at least a 12% prevalence of pla-
cental malaria, a 30% effect of the other intervention, and a
10% loss to follow-up. All analyses followed the intent-to-
treat principle. χ2 tests of independence or Fisher’s exact
tests and Wilcoxon rank-sum test were used to compare
study outcomes between those who received vitamin A or
placebo and zinc or placebo. Twin pregnancies were ana-
lyzed as a single outcome. The final birthweight for twin
pregnancies was the average of the two twin birthweights.
If either of the twins was stillborn, low birthweight, or SGA,
the pregnancy was classified as such. Exclusion of twins
from the birthweight analyses in a post hoc sensitivity
analysis did not change our findings. The presence of
interaction between vitamin A and zinc was evaluated by
comparing nested log-binomial models with and without
cross product terms for the two nutrients using the likeli-
hood ratio test. Potential selection bias due to incomplete
placenta collection was evaluated using marginal structural
models (MSMs) weighted by the inverse probability of hav-
ing a placental sample collected.26 Weights were calculated
as the inverse of predicted values from a logistic regres-
sion model of inclusion in the primary endpoint analyses
containing the following variables: treatment arm, baseline
FIGURE 1. Study enrollment, randomization, and pregnancy outcomes.
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maternal characteristics, household characteristics, compli-
ance with the regimen, and pairwise interactions between
treatment and all maternal and household characteristics.
The effect of supplementation was then estimated using
weighted log-binomial models with empirical standard
errors.27 All P values were two-sided. SAS version 9.2 (SAS
Institute Inc., Cary, NC) was used for all analyses.
The Harvard TH Chan School of Public Health Human
Subjects Committee, the MUHAS Senate Research and
Publications Committee, and Tanzania’s National Institute
for Medical Research granted institutional review board
approval for the study. The Tanzania Food and Drugs
Authority approved the use of the supplements. Study
progress was monitored by a Data safety monitoring
board annually.
RESULTS
A total of 2,500 screened participants were enrolled in
the trial. The trial profile is shown in Figure 1. It was not
possible to collect placentas from 875 participants for the
following reasons: miscarriages (fetal loss before 28 weeks
of gestation) (N = 234), delivery outside of Dar es Salaam or
at a non-study hospital (N = 577), or withdrawal from the
study (N = 34). Of the remaining 1,589 women, 1,404 pla-
cental samples were obtained (88%); histology results were
available for 1,361 participants. PCR results were available
for 1,158 participants, and 1,404 participants had either
histology or PCR results available.
Baseline characteristics of the 1,404 participants with
placental malaria results and the 1,096 participants with-
out these results are shown in Table 1. A higher propor-
tion of participants excluded from the placental malaria
analyses due to missing data owned their housing com-
pared with those included in the analysis (26% versus
21%). No other differences in baseline characteristics were
apparent between those included in and excluded from the
primary outcome analyses.
Table 2 displays the baseline characteristics by treatment
arm among the participants included in the primary out-
come analyses. No differences in baseline characteristics
were seen between those who did and did not receive vita-
min A and those who did and did not receive zinc. Use
of all malaria interventions exceeded 90% in all groups. The
mean gestational age at randomization was 10 weeks and
was comparable across treatment groups. The average
compliance rate (number of tablets absent from returned
regimen bottles divided by the number of days the
TABLE 1
Baseline characteristics of participants included and excluded from the PM analyses at baseline by randomization arm
Characteristic Included in analysis of PM (N = 1,404) Excluded from analysis of PM (N = 1,096)
Age (years) 22.9 (4.4) 22.5 (4.4)
Primigravida 48% 48%
Gestational age at randomization (weeks) 10.0 (2.3) 9.8 (2.5)
Education (years)
0 to < 5 8% 9%
5 to < 8 64% 62%
8 to < 12 23% 25%
≥ 12 5% 5%
Marital status
Married/cohabitating 90% 91%
Other 10% 9%
Employment status
Skilled 6% 5%
Unskilled or informal 24% 25%
Housewife/unemployed 55% 57%
Other 15% 13%
Housing type
Own 21% 26%
Rent 72% 66%
Other 7% 9%
Roof
Metal 99% 98%
Other 1% 2%
Floor
Concrete 97% 97%
Tile 2% 2%
Dirt or wood 1% 1%
Malaria interventions
Uses spray, coils, or bednet at night 94% 94%
Has bednet 93% 92%
Regularly uses bednet 92% 90%
Body mass index (kg/m2) 23.3 (4.4) 23.1 (4.3)
Body mass index category
< 18.5 11% 10%
18.5–24.9 60% 63%
≥ 25 29% 27%
Baseline mid-upper arm circumference (mm) 26.2 (3.5) 26.3 (3.4)
Baseline hemoglobin (g/dL) 11·5 (1.5) 11·6 (1.5)
PM = placental malaria.
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participant had the bottle) was 84.5% (median 97.6%).
Average compliance rate was similar between groups.
The prevalence of placental malaria detected through
histopathology was 8.5% (115/1,361), whereas the prev-
alence detected by PCR was 14.8% (171/1,158). The
Spearman correlation between the two diagnostic methods
was 0.11. Those who received zinc had a lower risk of
histopathology-positive placental malaria than those who did
not receive zinc in unweighted models (risk ratio [RR] =
0.64, 95% confidence interval [CI] = 0.44, 0.91; Table 3);
results from MSMs were virtually identical (RR = 0.62,
95% CI = 0.42, 0.89). However, vitamin A administration
had no impact on histopathology-positive infection, and
neither nutrient affected PCR-positive placental malaria.
All infections detected by PCR and histopathology were
P. falciparum.
Effects of vitamin A and zinc supplementation on second-
ary outcomes are presented in Table 4. Although neither
supplement affected birthweight among the 2,056 partici-
pants with birthweight data available, there was a nonsignif-
icant tendency for higher placental weight who received
vitamin A compared with those who did not (442 ± 119 g
TABLE 2
Baseline characteristics by treatment arm among the participants included in the primary outcome analyses (Mean SD or %)
Characteristic Vitamin A (N = 697) No vitamin A (N = 707) Zinc (N = 694) No zinc (N = 710)
Age (years) 23.0 (5.0) 22.7 (3.7) 23.0 (4.8) 22.7 (4.0)
Primigravida 46% 49% 48% 47%
Gestational age at randomization (weeks) 10.0 (2.4) 10·0 (2.3) 10.1 (2.4) 10.0 (2.3)
Education (years)
0 to < 5 9% 6% 7% 8%
5 to < 8 63% 66% 65% 63%
8 to < 12 21% 23% 21% 24%
≥ 12 7% 4% 6% 5%
Marital status
Married/cohabitating 89% 90% 91% 89%
Other 11% 10% 11% 9%
Employment status
Skilled 6% 5% 6% 5%
Unskilled or informal 24% 23% 24% 24%
Housewife/unemployed 53% 57% 55% 55%
Other 17% 14% 15% 16%
Housing type
Own 26% 25% 25% 27%
Rent 65% 67% 66% 65%
Other 9% 8% 9% 8%
Roof
Metal 99% 98% 98% 99%
Other 1% 2% 1% 1%
Floor
Concrete 97% 97% 97% 98%
Tile 1% 2% 2% 1%
Dirt or wood 1% 1% 1% 1%
Malaria interventions
Uses spray, coils, or bednet at night 93% 95% 94% 94%
Has bednet 92% 94% 94% 93%
Regularly uses bednet 90% 93% 92% 91%
Body mass index (kg/m2)* 23.3 (4.5) 23.4 (4.3) 23.3 (4.3) 23.4 (4.5)
Body mass index category (kg/m2)
18.5 11% 10% 10% 11%
18.5–24.9 61% 60% 61% 60%
≥ 25 28% 30% 29% 28%
Baseline mid-upper arm circumference (mm) 26.1 (3.5) 26.3 (3.6) 26.3 (3.5) 26.2 (3.5)
Baseline hemoglobin (g/dL) 11.4 (1.4) 11.5 (1·5) 11.4 (1.5) 11.5 (1.4)
TABLE 3
Effect of vitamin A and zinc supplementation on placental malaria*
Outcome
Vitamin A Zinc
Yes N No N RR (95% CI) P Yes N No N RR (95% CI) P
Unweighted model†
Histopathology positive 57 (8) 679 58 (9) 682 0.99 (0.70, 1.40) 0.94 44 (7) 671 71 (10) 690 0.64 (0.44, 0.91) 0.01
PCR positive 88 (15) 579 83 (14) 579 1.06 (0.80, 1.40) 0.68 90 (16) 580 81 (14) 578 1.11 (0.84, 1.46) 0.47
Marginal structural models
Histopathology positive 1.03 (0.82, 1.29) 0.62 (0.42, 0.89)
PCR positive 1.00 (0.70, 1.45) 0.89 (0.71, 1.12)
CI = confidence interval; PCR = polymerase chain reaction; RR = risk ratio.
*Mean (standard deviation) for continuous variables and N (%) for dichotomous variables.
†Twenty-five participants had both histopathology- and PCR-positive infections.
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versus 430 ± 111 g; P = 0.08) and among those who
received zinc than those who did not (443 ± 116 g versus
431 ± 114 g; P = 0.05) (Table 2). Those who received vita-
min A had an increased risk of severe anemia (RR = 1.36,
95% CI = 1.05, 1.76) compared with those who did not. In
addition, we observed a statistically nonsignificant trend
toward a lower risk of very preterm birth among those who
received vitamin A compared with those who did not (RR =
1.34, 95% CI = 0.95, 1.89). Neither vitamin A nor zinc
supplementation was associated with fetal loss, perinatal
death, infant mortality, low birthweight, SGA, or any other
outcomes measured. No interaction between vitamin A and
zinc was observed for any outcome (all P > 0.05). No safety
concerns were identified for either intervention.
DISCUSSION
This study is the first to examine the impact of vitamin A
and zinc supplementation starting in early pregnancy on
placental malaria. We observed that supplementation with
25 mg zinc per day from the first trimester until delivery
was associated with a 36% (95% CI = 9–56%) reduced risk
of histopathology-positive placental infection, but not PCR-
positive infection. Vitamin A supplementation had no impact
on placental malaria, but was associated with an increased
risk for severe anemia.
Some caution is warranted in the interpretation of these
observations. Because placental malaria results were unavail-
able from a large proportion (46%) of participants, the possibility
of selection bias stemming from potential nonrandomness of
treatment allocation among those with results available
must be considered. Although Table 1 indicates that those
included in and excluded from the placental malaria analy-
ses had comparable covariate profiles, we attempted to
correct for this potential bias through the use of MSMs.
This technique uses weights to create a statistical pseudo-
population in which the distribution of baseline characteris-
tics across treatment assignment reflects the distribution
that would have been observed had no attrition occurred.
The similarity of the results between the weighted and
unweighted models suggests that selection bias did not
likely affect our findings. At the same time, this proportion
of subjects lost to follow-up was higher than assumed in
the power calculations and may have reduced the precision
of our estimates.
Another potential source of bias in this study is the
use of date of LMP to determine gestational age, which
was necessary due to the unavailability of ultrasound in
this setting. Inaccurate recollection of this date may
have introduced some misclassification of preterm birth
and SGA. Because LMP dates were ascertained before
these outcomes occurred, this misclassification is likely
nondifferential and would bias our results toward the null.
In a comparable Nigerian population,28 91% of partici-
pants’ estimated gestational ages based on their date of
LMP were within 2 weeks of their ultrasound-confirmed
gestational ages. However, we expect that recall accu-
racy may be slightly higher in our study, because women
were enrolled earlier in pregnancy. Our study has several
strengths, including its factorial design, long duration of
supplementation, and excellent rate of compliance and
overall follow-up.
We observed a lack of agreement between histopa-
thology and PCR-based diagnoses. Because the sensi-
tivity and specificity differ between these two diagnostic
methods, some disagreement is expected. A study per-
formed among 272 Mozambican pregnant women found
that placental histology had a sensitivity of 41.8% and a
specificity of 97.1% when compared with PCR.29 Consis-
tent with their findings, the prevalence of placental malaria
was higher when determined by PCR, but we observed
a much larger proportion of histology-positive and PCR-
negative diagnoses. Placental histology may miss posi-
tive cases or lead to false-positive diagnoses due to the
difficulty in distinguishing hemozoin and other artefactual
pigment, but it is nonetheless still considered the “gold
standard” for accuracy. It is unclear why zinc supplemen-
tation was associated with a reduction in malaria detected
through histopathology and not PCR, and the discrepancy
suggests additional caution in interpreting our results.
Previous trials to evaluating the effect of zinc supple-
mentation on malaria outcomes among pregnant women
and children have provided similarly mixed results. A trial
from Ghana involving 364 pregnant women reported a
small absolute reduction (3.2%) in malaria parasitemia
among those who received iron and zinc supplementation
compared with those who received iron supplementation
alone.18 In Papua New Guinea, zinc supplementation was
associated with a 38% (95% CI = 3–60; P = 0.037) reduc-
tion in P. falciparum health center–based episodes in a
trial conducted among 274 preschool children.13 Com-
bined supplementation with zinc and vitamin A reduced
malaria incidence by 30% in children in Burkina Faso, but
the design of this study precludes attribution of the effect
to either nutrient alone.15 Other studies conducted among
children have found no evidence that zinc supplementa-
tion prevents malaria.14,16
Zinc deficiency is common in sub-Saharan Africa, and
pregnant women may be especially vulnerable to this con-
dition. Diets in some African settings are predominantly
cereal based and rich in phytates that impair zinc absorp-
tion; additionally there is often poor intake of flesh food, a
good source of available zinc.30 Using national data on
stunting rates and the adequacy of zinc in the national food
supply, the International Zinc Nutrition Consultative Group
estimates that 44% of Tanzanians are at risk of inadequate
zinc intake.31 Zinc deficiency is detrimental to several
aspects of adaptive and innate immunity, as reviewed by
Shankar and Prasad.32 While our results require replication,
it is plausible that improving zinc status through supple-
mentation among pregnant women could lead to increased
immunity against histopathologically detectable infection.
Though we did not observe a corresponding decrease in
adverse birth outcomes among zinc-supplemented partici-
pants, other factors such as poor maternal nutritional sta-
tus and multiple micronutrient deficiencies may have also
contributed to the development of these outcomes in this
resource-constrained setting.33
Our observation that vitamin A was associated with
increased risk of severe anemia is unexpected. A recent
meta-analysis shows that vitamin A supplementation in
pregnancy improves hemoglobin levels and reduces anemia
risk; however, vitamin A supplementation was initiated later
in pregnancy than in our study.20 While it is possible that
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our finding may represent an adverse effect of prolonged
vitamin A exposure, little observational or experimental evi-
dence exists to support this, and our finding may therefore
be attributable to chance. We saw no difference in overall
anemia risk associated with vitamin A supplementation.
We observed no other differences in adverse birth out-
comes associated with either supplement. These findings
largely confirm those of meta-analyses19,20 and are notable
for showing that these supplements may provide no benefit
to pregnancy maintenance or fetal growth even when initi-
ated during the first trimester. While our findings do not
support the 14% reduction in preterm birth associated with
zinc reported in a Cochrane review that pooled 16 supple-
mentation trials involving 7,637 women,19 a much larger
trial would be necessary to detect a significant effect of this
modest size.
Our results may be generalizable to settings where
malaria is well controlled as in Dar es Salaam where preven-
tive interventions include high bednet coverage, systematic
spraying of insecticides, and provision of intermittent pre-
ventive therapy to pregnant women as standard of care.34
For this reason, trials in other geographic locations are
needed. In conclusion, our trial has provided modest sup-
port of a potential benefit of zinc supplementation to prevent
histopathologically detectable placental malaria. If this find-
ing is confirmed in additional studies, zinc supplementation
could be considered as a low-cost addition to malaria con-
trol measures aimed at reducing the risk of malaria in preg-
nant women.
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